Talzenna® (talazoparib) – New indication
June 20, 2023 - Pfizer announced the FDA approval of Talzenna (talazoparib), in combination with Xtandi® (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Top